Clinical Trial Explores Bimatoprost as Male Hair Loss Treatment
Makers of a glaucoma drug that has also been used as a key ingredient in cosmetic treatments to make eyelashes longer have announced plans for a new trial into its potential use combating hair loss from Male Pattern Baldness.
Allergan, which has headquarters in Dublin and New Jersey, hope to recruit 90 people with male pattern hair loss for a one-year study into what effect their drug Bimatoprost has on their scalps. They will be using different concentrations and formulations of the drug on different subjects and state that their objectives are to measure adverse effects, its tolerability and its effects on plasma levels. It seems that there will be no study into the efficacy of the drug as a possible hair loss medication during this specific trial.
It is not the first time that Allergan has conducted clinical trials into the use of its drugs on people with hair loss: an a mid-stage trial report suggested it had failed to demonstrate sufficient efficacy to proceed to a late stage study.
The news at the time was met with some disappointment across the hair loss industry, as initial laboratory research into the product suggested it showed promise as a possible future treatment for MPB. When tested on living scalp tissues, follicles that were treated grew by a third more than untreated tissue in nine days.
The new trial will shortly be looking for test subjects with mild to moderate MPB with ongoing hairloss for at least a year. The company further state that participants should be between 18 and 49 years, and that anyone who currently applies topical applications of the medically-proven hair loss medication minoxidil needs to have stopped using it at least four weeks before the trial starts.
Whilst bimatoprost is still in development, there are of course other effective hair loss treatment options available now for men currently concerned about their thinning hair or a receding hairline.
There are two clinically-proven medications for male pattern baldness that people typically turn to when their hair starts to thin - one oral and one topical. These MHRA licensed and FDA approved solutions can be used individually or in tandem, depending on the individual's suitability and wishes, to help deter the cause of genetic hair thinning and to promote hair growth.
Further supplementary hair growth supporting products can also be combined with either or both products.
Anyone noticing signs of hair loss and wanting to explore non-surgical options for preventing baldness is best advised to have a consultation with a hair specialist who can take them through everything from diagnosis to treatment recommendations.
Allergan, which has headquarters in Dublin and New Jersey, hope to recruit 90 people with male pattern hair loss for a one-year study into what effect their drug Bimatoprost has on their scalps. They will be using different concentrations and formulations of the drug on different subjects and state that their objectives are to measure adverse effects, its tolerability and its effects on plasma levels. It seems that there will be no study into the efficacy of the drug as a possible hair loss medication during this specific trial.
Previous clinical trial delayed
It is not the first time that Allergan has conducted clinical trials into the use of its drugs on people with hair loss: an a mid-stage trial report suggested it had failed to demonstrate sufficient efficacy to proceed to a late stage study.
The news at the time was met with some disappointment across the hair loss industry, as initial laboratory research into the product suggested it showed promise as a possible future treatment for MPB. When tested on living scalp tissues, follicles that were treated grew by a third more than untreated tissue in nine days.
The new trial will shortly be looking for test subjects with mild to moderate MPB with ongoing hairloss for at least a year. The company further state that participants should be between 18 and 49 years, and that anyone who currently applies topical applications of the medically-proven hair loss medication minoxidil needs to have stopped using it at least four weeks before the trial starts.
Treatment for male pattern hair loss
Whilst bimatoprost is still in development, there are of course other effective hair loss treatment options available now for men currently concerned about their thinning hair or a receding hairline.
There are two clinically-proven medications for male pattern baldness that people typically turn to when their hair starts to thin - one oral and one topical. These MHRA licensed and FDA approved solutions can be used individually or in tandem, depending on the individual's suitability and wishes, to help deter the cause of genetic hair thinning and to promote hair growth.
Further supplementary hair growth supporting products can also be combined with either or both products.
Anyone noticing signs of hair loss and wanting to explore non-surgical options for preventing baldness is best advised to have a consultation with a hair specialist who can take them through everything from diagnosis to treatment recommendations.
The Belgravia Centre
The Belgravia Centre is a world-renowned group of a hair loss clinic in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation from anywhere in the world for home-use treatment.
View our Hair Loss Success Stories, which includes the world's largest gallery of hair growth photos and demonstrates the level of success that so many of Belgravia's patients achieve.
